Free tool
FAERS Monitor: Imkeldi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219097 or its brand name (Imkeldi, Imatinib Mesylate). Reports on generic versions are filed under their own applications.
Reports
9
Serious
9
100% of reports
Hospitalization
8
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hospitalisation3
- pneumonia2
- therapy interrupted2
- blister1
- blood bilirubin increased1
- cardiogenic shock1
- catheterisation cardiac1
- dependence on respirator1
- dysphagia1
- dyspnoea1
- electrolyte imbalance1
- erythema1
- febrile neutropenia1
- fluid retention1
- hyponatraemia1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 1 |
| 2025 | 2 |
| 2026 | 6 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,150 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dependence on respirator | 1 | 5848.4 | 919.1 | 1,457 |
| catheterisation cardiac | 1 | 527.2 | 83.1 | 131 |
| electrolyte imbalance | 1 | 201.2 | 31.7 | 49 |
| cardiogenic shock | 1 | 162.9 | 25.7 | 40 |
| blood bilirubin increased | 1 | 86.5 | 13.6 | 21 |
| therapy interrupted | 2 | 65.4 | 19.3 | 71 |
| fluid retention | 1 | 46.0 | 7.2 | 11 |
| hospitalisationSignal | 3 | 45.6 | 18.1 | 91 |
| blister | 1 | 41.6 | 6.6 | 9 |
| hyponatraemia | 1 | 41.5 | 6.5 | 9 |
| febrile neutropenia | 1 | 35.2 | 5.6 | 8 |
| dysphagia | 1 | 24.6 | 3.9 | 5 |
| pneumonia | 2 | 14.4 | 4.3 | 14 |
| erythema | 1 | 11.4 | 1.8 | 2 |
| dyspnoea | 1 | 4.1 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.